WO2008089491A2 - Modifications of peptide compositions to increase stability and delivery efficiency - Google Patents

Modifications of peptide compositions to increase stability and delivery efficiency Download PDF

Info

Publication number
WO2008089491A2
WO2008089491A2 PCT/US2008/051706 US2008051706W WO2008089491A2 WO 2008089491 A2 WO2008089491 A2 WO 2008089491A2 US 2008051706 W US2008051706 W US 2008051706W WO 2008089491 A2 WO2008089491 A2 WO 2008089491A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
composition
carrier
cargo
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/051706
Other languages
English (en)
French (fr)
Other versions
WO2008089491A3 (en
Inventor
Derek Maclean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Priority to AU2008206077A priority Critical patent/AU2008206077A1/en
Priority to KR1020157036605A priority patent/KR101775929B1/ko
Priority to CN2008800085591A priority patent/CN101675067B/zh
Priority to EP08728081.4A priority patent/EP2109619B1/en
Priority to KR1020197036654A priority patent/KR102274003B1/ko
Priority to EP17161141.1A priority patent/EP3248985B1/en
Priority to JP2009546577A priority patent/JP2010516707A/ja
Priority to KR1020177024556A priority patent/KR20170104634A/ko
Priority to CA2675665A priority patent/CA2675665C/en
Publication of WO2008089491A2 publication Critical patent/WO2008089491A2/en
Publication of WO2008089491A3 publication Critical patent/WO2008089491A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)

Definitions

  • Figure 4 shows illustrate the conversion of a therapeutic peptide comprising a carrier peptide and a cargo peptide linked via a disulfide bond to a therapeutic peptide in linear form.
  • This linear peptide (KP-01547) has been capped at its amino and carboxy termini and contains a short amino acid sequence linker.
  • an aliphatic residue is placed at the penultimate carboxy terminal position of the peptide to reduce the rate of disulfide bond exchange.
  • the aliphatic residue can be place at either the amino terminal or carboxy terminal side of the residue, or at both sides.
  • Disulfide bond exchange can be eliminated completely by linking the carrier and cargo peptides to form a single, linear peptide. This method is discussed below.
  • Residues in the recognition sequence can be moved or removed to destroy the recognition site.
  • a conservative substitution is made with one or more of the amino acids which comprise an identified protease recognition site.
  • the side chains of these amino acids possess a variety of chemical properties.
  • the most common amino acids are categorized into 9 groups, listed below. Substitution within these groups is considered to be a conservative substitution.
  • carrier and cargo peptides are linked by a peptide bond to form a linear peptide.
  • Stability and potency of the therapeutic peptides can also be increased through the construction of peptide multimers, wherein a plurality of cargo peptides is linked to one or more carrier peptides.
  • An additional embodiment of the invention involving a cleavable linker sequence is also discussed.
  • carries include octa-Arg, octa-D-Arg, and Antennapedia derived peptides, which are known in the art.
  • Modification of the carrier showed the great propensity in improving the half life of the composition while modification of the cargo showed little effect.
  • CELGSLQAEDD linked to a TAT peptide with a N-Term Cys, which is capped at both ends and disulfide conjugated to the cargo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PCT/US2008/051706 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency Ceased WO2008089491A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2008206077A AU2008206077A1 (en) 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency
KR1020157036605A KR101775929B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
CN2008800085591A CN101675067B (zh) 2007-01-19 2008-01-22 肽组合物的修饰以提高稳定性和递送效率
EP08728081.4A EP2109619B1 (en) 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency
KR1020197036654A KR102274003B1 (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
EP17161141.1A EP3248985B1 (en) 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency
JP2009546577A JP2010516707A (ja) 2007-01-19 2008-01-22 ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
KR1020177024556A KR20170104634A (ko) 2007-01-19 2008-01-22 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
CA2675665A CA2675665C (en) 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88141907P 2007-01-19 2007-01-19
US60/881,419 2007-01-19
US94528507P 2007-06-20 2007-06-20
US60/945,285 2007-06-20

Publications (2)

Publication Number Publication Date
WO2008089491A2 true WO2008089491A2 (en) 2008-07-24
WO2008089491A3 WO2008089491A3 (en) 2008-11-27

Family

ID=39636771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/051706 Ceased WO2008089491A2 (en) 2007-01-19 2008-01-22 Modifications of peptide compositions to increase stability and delivery efficiency

Country Status (8)

Country Link
US (7) US8067532B2 (enExample)
EP (2) EP2109619B1 (enExample)
JP (7) JP2010516707A (enExample)
KR (4) KR102274003B1 (enExample)
CN (3) CN101675067B (enExample)
AU (1) AU2008206077A1 (enExample)
CA (2) CA2675665C (enExample)
WO (1) WO2008089491A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010111533A3 (en) * 2009-03-25 2010-11-18 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
US8377880B2 (en) 2009-07-29 2013-02-19 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
WO2013128003A1 (en) * 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
US8969299B2 (en) 2011-06-08 2015-03-03 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
US8987200B2 (en) 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
WO2021002408A1 (ja) 2019-07-02 2021-01-07 Ａｇｃ株式会社 ペプチド及びその製造方法
US11162500B2 (en) 2013-06-28 2021-11-02 Amgen Inc. Stable liquid formulation of AMG 416 (etelcalcetide)
WO2023048236A1 (ja) 2021-09-22 2023-03-30 Ａｇｃ株式会社 ペプチド
WO2025135179A1 (ja) 2023-12-22 2025-06-26 Ａｇｃ株式会社 蛍光増強剤

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8067532B2 (en) * 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
HK1245671A1 (zh) 2015-05-29 2018-08-31 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
BR112018011096A2 (pt) * 2015-12-02 2018-12-04 Inst Nat De La Rech Agronomique Inra novos peptídeos que têm atividade antimicrobiana e nova enzima capaz de converter resíduo de configuração l em aminoácido de configuração d em um peptídeo
EP3411387A4 (en) 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. SIGNAL MOLECULES AS A CELL PENETRANT
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
KR101772449B1 (ko) * 2016-12-27 2017-08-30 주식회사 하이센스바이오 신규한 펩타이드
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
MX2020010071A (es) * 2018-03-29 2021-01-08 Contrafect Corp Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
GB201903873D0 (en) * 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
EP4058466A1 (en) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
WO2021195254A1 (en) * 2020-03-24 2021-09-30 Young Therapeutics, Llc Protein kinase c modulators
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
KR102380732B1 (ko) 2021-09-23 2022-04-04 엘이솔루션 주식회사 축산분뇨처리시스템
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007413A2 (en) 2000-07-13 2002-01-24 Eldad Ben Asher An electronic circuit for reducing the danger of exposure to radiation from a transmitter

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615977A (en) * 1898-12-13 Car-fender
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
US20030108539A1 (en) 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1267904A4 (en) * 2000-02-16 2006-02-08 Univ Northwestern POLYPEPTOIDE PULMONARY SURFACTANTS
JP3710368B2 (ja) 2000-09-25 2005-10-26 シャープ株式会社 積層フィルムの製造方法
IL155204A0 (en) * 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
CA2434643C (en) 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
WO2003084985A1 (fr) * 2002-04-11 2003-10-16 Mochida Pharmaceutical Co., Ltd. Peptide chimiquement modifie a l'aide de polyethyleneglycol
JP2005523326A (ja) 2002-04-22 2005-08-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ プロテインキナーゼｃのペプチドインヒビター
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
AU2003294401C1 (en) * 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
AU2004215133B2 (en) 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
WO2004084805A2 (en) * 2003-03-19 2004-10-07 The J. David Gladstone Institutes Acetylated tat polypeptides and methods of use thereof
AU2004235396B2 (en) * 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US20050187156A1 (en) * 2003-12-11 2005-08-25 Daria Mochly-Rosen Isozyme-specific antagonists of protein kinase C
EP1784483A2 (en) 2004-08-02 2007-05-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
US7265092B2 (en) * 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP4596391B2 (ja) * 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
JP5116663B2 (ja) * 2005-04-15 2013-01-09 アリゾナ バイオメディカル リサーチ コミッション 転移癌の処置のための治療用ペプチド
WO2007035782A2 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
US7741290B2 (en) * 2006-06-01 2010-06-22 The Board of Trustee of The Leland Stanford Juinior University Method of preventing progression of hypertension-induced heart failure with PKC peptides
AU2007305268A1 (en) * 2006-10-02 2008-04-10 The Board Of Trustees Of The Leland Stanford Junior University Peptides derived from the C2 domain of epsilon PKC, and use thereof
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
US8067532B2 (en) * 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US8017583B2 (en) * 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007413A2 (en) 2000-07-13 2002-01-24 Eldad Ben Asher An electronic circuit for reducing the danger of exposure to radiation from a transmitter

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987200B2 (en) 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
WO2010111533A3 (en) * 2009-03-25 2010-11-18 Kai Pharmaceuticals, Inc. Transdermal delivery of pkc modulatory peptides through microporated skin
US9701712B2 (en) 2009-07-29 2017-07-11 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US8377880B2 (en) 2009-07-29 2013-02-19 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US10280198B2 (en) 2009-07-29 2019-05-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US9278995B2 (en) 2009-07-29 2016-03-08 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US9567370B2 (en) 2009-07-29 2017-02-14 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
US8969299B2 (en) 2011-06-08 2015-03-03 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
EP2820150A1 (en) * 2012-03-01 2015-01-07 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
WO2013128003A1 (en) * 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
US11162500B2 (en) 2013-06-28 2021-11-02 Amgen Inc. Stable liquid formulation of AMG 416 (etelcalcetide)
US11959486B2 (en) 2013-06-28 2024-04-16 Amgen Inc. Stable liquid formulation of AMG 416 (etelcalcetide)
WO2021002408A1 (ja) 2019-07-02 2021-01-07 Ａｇｃ株式会社 ペプチド及びその製造方法
WO2023048236A1 (ja) 2021-09-22 2023-03-30 Ａｇｃ株式会社 ペプチド
WO2025135179A1 (ja) 2023-12-22 2025-06-26 Ａｇｃ株式会社 蛍光増強剤

Also Published As

Publication number Publication date
CN108948144A (zh) 2018-12-07
JP2010516707A (ja) 2010-05-20
US20120178138A1 (en) 2012-07-12
KR101775929B1 (ko) 2017-09-07
US8067532B2 (en) 2011-11-29
EP3248985A1 (en) 2017-11-29
US9255124B2 (en) 2016-02-09
US20160208237A1 (en) 2016-07-21
CA2989778A1 (en) 2008-07-24
US10077438B2 (en) 2018-09-18
KR20160005377A (ko) 2016-01-14
KR20170104634A (ko) 2017-09-15
AU2008206077A1 (en) 2008-07-24
US20180371448A1 (en) 2018-12-27
JP2025185093A (ja) 2025-12-18
JP2018111717A (ja) 2018-07-19
JP2021098725A (ja) 2021-07-01
US20250034545A1 (en) 2025-01-30
CA2675665C (en) 2018-02-13
CA2989778C (en) 2020-06-30
JP2016147905A (ja) 2016-08-18
EP2109619A2 (en) 2009-10-21
WO2008089491A3 (en) 2008-11-27
KR20190140111A (ko) 2019-12-18
US20200370032A1 (en) 2020-11-26
EP3248985B1 (en) 2019-10-23
JP2014224126A (ja) 2014-12-04
US20090042769A1 (en) 2009-02-12
CN103524623A (zh) 2014-01-22
EP2109619A4 (en) 2013-04-24
JP5937643B2 (ja) 2016-06-22
CN101675067A (zh) 2010-03-17
KR20090115852A (ko) 2009-11-09
US20220282239A1 (en) 2022-09-08
EP2109619B1 (en) 2017-05-03
KR102274003B1 (ko) 2021-07-08
CA2675665A1 (en) 2008-07-24
JP2023078424A (ja) 2023-06-06
CN101675067B (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
US20250034545A1 (en) Modifications of peptide compositions to increase stability and delivery efficiency
US7893023B2 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
AU715632B2 (en) Conjugates useful in the treatment of prostate cancer
KR20170043509A (ko) 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
EP2753636A2 (en) Compstatin analogs with improved pharmacokinetic properties
AU8396098A (en) Conjugates useful in the treatment of prostate cancer
NZ504615A (en) Conjugates useful in the treatment of prostate cancer
FRIIS Peptide and protein derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880008559.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08728081

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2675665

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009546577

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 578525

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008206077

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097017122

Country of ref document: KR

REEP Request for entry into the european phase

Ref document number: 2008728081

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008728081

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008206077

Country of ref document: AU

Date of ref document: 20080122

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020157036605

Country of ref document: KR